Ambu Settles US Defense Department False-Claims Allegations
Executive Summary
Danish device-maker Ambu has agreed to pay $3.3m to resolve allegations of False Claims Act violations. The company is said to have made medical product in Malaysia and China for sale to the Departments of Defense and Veterans Affairs, which is forbidden under the Trade Agreements Act.
You may also be interested in...
Medtronic Settles On Country-Of-Origin Allegations
The suit follows similar charges against Smith & Nephew. In both instances, the companies are alleged to have sold devices to the federal government that were made in China or other countries that do not have trade agreements with the U.S. but repackaged and relabeled as made in the U.S.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.